Aton EBIT per Share
EBIT per Share of Aton (ALTAO.PA) as of Aug 5, 2026.
Get this data via API
Financial Data API
EBIT per Share
-0.00EUR
YoY
-88.21%
Last updated:
EBIT per Share of Aton is 2026 -0.00 EUR. EBIT per Share of Aton was 2025 -0.01 EUR. It decreases by -88.21% higher compared to the previous year.
Access this data via the Eulerpool API
Aton Stock analysis
What does Aton do? Hybrigenics SA is a French company that was founded in 1997 to develop innovative technologies for the discovery and development of new drugs. The company specializes in the identification of proteins responsible for the development of cancer and other diseases, as well as the development of therapies for these diseases. It is headquartered in Paris and has branches in the United States and Japan. Hybrigenics has become a leading provider of protein research technologies since its founding, employing approximately 50 employees including scientists, engineers, and technicians. The company's business model is based on developing innovative technologies for drug discovery and development. It conducts research and development in the field of protein research, particularly protein interaction analysis. The company aims to better understand the mechanism of action of proteins involved in disease development in order to develop targeted therapies. Hybrigenics collaborates closely with its customers to develop tailored solutions for their specific research needs. It provides a range of products and services including proteomic services, screening tools, data analysis software, and platform technologies. The company is divided into different divisions, including proteomic services, screening tools, data analysis software, and platform technologies. Some of the key divisions include proteomic services, which offer customers proteomic services based on decades of experience in protein research and analysis. These services allow customers to identify new proteins involved in specific diseases and also provide protein interaction analysis services to better understand the mechanism of action of disease proteins. Hybrigenics offers screening tools that allow customers to quickly and easily investigate and compare different proteins. These tools are particularly useful for identifying proteins that can serve as indicators for specific diseases. The company also offers data analysis software that enables customers to quickly and accurately evaluate the results of their protein research. This software uses algorithms and artificial intelligence to analyze data and identify patterns. Hybrigenics has also developed a range of platform technologies to help customers optimize their protein research. These technologies include the yeast two-hybrid assay, which can be used to study protein interactions, as well as various technologies for protein expression and purification. Hybrigenics offers a variety of products tailored to its different divisions. Some of the key products include the PIII-Toolbox, a comprehensive platform technology for protein research that allows for fast and efficient identification of protein-protein interactions, HybriScreen Plus, a screening tool that helps customers quickly and easily investigate and compare different proteins, and the yeast two-hybrid assay, a platform technology for studying protein interactions to better understand the mechanism of action of disease proteins. Aton is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Aton stock
On Eulerpool you can find the complete historical development of EBIT per Share Aton since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Aton
All Key Metrics — Aton
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth